Spacesuits need a major upgrade for the next phase of exploration 
How do airplanes fly? An aerospace engineer explains the physics of flight 
The mystery of consciousness shows there may be a limit to what science alone can achieve 
Six space missions to look forward to in 2024 
Alpha, beta, theta: what are brain states and brain waves? And can we control them? 
What is minoxidil, the anti-balding hair growth treatment? Here’s what the science says 
Our survey of the sky is uncovering the secrets of how planets are born 
The brightest object in the universe is a black hole that eats a star a day 
Could a telescope ever see the beginning of time? An astronomer explains 
Why now is the time to address humanity’s impact on the moon 
Eggs from men, sperm from women: how stem cell science may change how we reproduce 
Why some people don't trust science – and how to change their minds 
Dark energy is one of the biggest puzzles in science and we're now a step closer to understanding it 
The brain is the most complicated object in the universe. This is the story of scientists’ quest to decode it – and read people’s minds 
If life exists on Jupiter’s moon Europa, scientists might soon be able to detect it 
Customizing mRNA is easy, and that's what makes it the next frontier for personalized medicine − a molecular biologist explains 
Finding the cure for cancer also requires scientists and researchers to find various strategies on how to heal or destroy cancer cells and tumors. A recently published study offers an interesting approach as it revealed that a vaccine might be able to “teach” the immune system in treating tumors by itself.
The study was published in Nature Medicine (EurekAlert!) in April by researchers from the renowned New York hospital Mount Sinai. The said vaccine is still under the experimental phase and is being called the “in situ vaccination.”
Reports have it that the scientists’ strategy is to inject “immune stimulants” directly to a tumor. This way, the immune system will recognize it and later heal a patient by destroying it and other tumors present in the body.
There were 11 patients who have been injected by this potential cancer cure and reportedly experienced positive results enough to merit a more advanced phase of clinical trials. Some of these cancer patients have reportedly been in remission for several months now because of the vaccine.
"The in situ vaccine approach has broad implications for multiple types of cancer," the study’s lead author Joshua Brody said. "This method could also increase the success of other immunotherapies such as checkpoint blockade." Dr. Brody is also the director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute in the Icahn School of Medicine of Mount Sinai.
The vaccine is reportedly administered with a couple of immune stimulants that work in different ways but all important to make the vaccine work. It starts by injecting immune stimulants that work to lead dendritic cells where the tumor is. The second one will activate the dendritic cells and awaken the T cells to subsequently destroy the tumors. The entire process then teaches the stimulants of the characteristics of the tumor allowing them to heal others in different parts of the body of the patient.
